Filtered By:
Drug: Vytorin

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891624 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Koh KK Tags: Circulation Source Type: research

Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891623 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Cordero A, Bertomeu-González V, Rodriguez-Mañero M Tags: Circulation Source Type: research

Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891622 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Thomopoulos C, Michalopoulou H Tags: Circulation Source Type: research

Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891621 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Del Pinto R, Ferri C, Borghi C Tags: Circulation Source Type: research

Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats.
In this study, we explored whether Eze could attenuate neuronal apoptosis in the rat model of middle cerebral artery occlusion (MCAO), specifically via activation of the AMPK/ULK1/autophagy pathway. Two hundred and one male Sprague-Dawley rats were subjected to transient MCAO followed by reperfusion. Eze was administered 1 h after MCAO. To elucidate the underlying molecular mechanism, Dorsomorphin, a selective AMPK inhibitor, and 3-methyladenine (3-MA), an autophagy inhibitor, were injected intracerebroventricularly before MCAO. Infarct volume, neurological score, brain cholesterol levels, immunofluorescence staining, We...
Source: Experimental Neurology - May 28, 2018 Category: Neurology Authors: Yu J, Li X, Matei N, McBride D, Tang J, Yan M, Zhang JH Tags: Exp Neurol Source Type: research

Ezetimibe With Statin Therapy for Stroke Prevention in ACS Ezetimibe With Statin Therapy for Stroke Prevention in ACS
Can the addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduce the frequency of ischemic stroke?Circulation
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis.
Abstract Since cardiovascular diseases are the main cause of mortality worldwide, the reduction of their risk is a crucial point of present-day medicine. It has been proven unequivocally that the administration of various treatments has a favorable effect on the frequency of cardiovascular events and on the atherosclerosis leading to them. Although systematic and guideline-driven administration of these drugs has led to a decrease in the incidence and mortality of vascular events, the leading position of this group of diseases in mortality and morbidity has not changed. That is why medicine, besides keeping up act...
Source: Orvosi Hetilap - January 1, 2018 Category: General Medicine Authors: Márk L, Harangi M, Paragh G Tags: Orv Hetil Source Type: research

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
Conclusions -In IMPROVE-IT the benefit of adding ezetimibe to statin was enhanced in patients with DM and in high-risk non-diabetics. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00202878. PMID: 29263150 [PubMed - as supplied by publisher]
Source: Circulation - December 20, 2017 Category: Cardiology Authors: Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E, IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Circulation Source Type: research

The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes, and the response to atorvastatin and EZE combination was similar for both men and women. PMID: 28553847 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 6, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
ConclusionReduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
Source: European Heart Journal - October 23, 2017 Category: Cardiology Source Type: research

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT.
Conclusions -The addition of ezetimibe to simvastatin in patients stabilized after ACS reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT00202878. PMID: 28972004 [PubMed - as supplied by publisher]
Source: Circulation - September 30, 2017 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E Tags: Circulation Source Type: research

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc the relationsh...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2017 Category: Urology & Nephrology Authors: Stanifer, J. W., Charytan, D. M., White, J., Lokhnygina, Y., Cannon, C. P., Roe, M. T., Blazing, M. A. Tags: Clinical Research Source Type: research

Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Authors: Wójcik C Abstract Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy...
Source: Postgraduate Medicine - September 9, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Lower Transaortic Flow Rate Is Associated With Increased Mortality in Aortic Valve Stenosis
Conclusions In patients with AS without known cardiovascular disease or diabetes, low transaortic FR was independently associated with higher rates of cardiovascular and all-cause mortality. (An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart) (MK-0653A-043 AM4); NCT00092677)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - August 7, 2017 Category: Radiology Authors: Saeed, S., Senior, R., Chahal, N. S., Lonnebakken, M. T., Chambers, J. B., Bahlmann, E., Gerdts, E. Tags: Original Research Source Type: research

Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
CONCLUSIONS: Main manifestations of ASCVD in FH patients were premature, multivessel CAD with need for recurrent revascularization, associated with classical cardiovascular risk factors but not with peak LDL-C. In spite of intensive therapy with lipid-lowering agents, treatment gaps were significant, with low attainment of LDL-C treatment goals. PMID: 28701632 [PubMed - as supplied by publisher]
Source: Circulation Journal - July 12, 2017 Category: Cardiology Authors: Zafrir B, Jubran A, Lavie G, Halon DA, Flugelman MY, Shapira C Tags: Circ J Source Type: research